Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.
Original language | English |
---|---|
Journal | Journal of Clinical Endocrinology and Metabolism |
Volume | 96 |
Issue number | 4 |
Pages (from-to) | 945-954 |
Number of pages | 10 |
ISSN | 0021-972X |
DOIs | |
Publication status | Published - 2011 |
Keywords
- Adamantane
- Administration, Oral
- Adult
- Aged
- Blood Glucose
- Cross-Over Studies
- Diabetes Mellitus, Type 2
- Dipeptidyl Peptidase 4
- Dipeptidyl-Peptidase IV Inhibitors
- Female
- Glucose
- Humans
- Incretins
- Injections, Intravenous
- Insulin
- Male
- Middle Aged
- Nitriles
- Pyrrolidines
- Up-Regulation